Table 2.
Cabazitaxel exposure
| All patients | Unmatched patients | Matched patients | |||
|---|---|---|---|---|---|
| C20 | C25 | C20 | C25 | ||
| N | 660 | 190 | 159 | 112 | 112 |
| Number of cycles | |||||
| Mean ± SD | 5.5 ± 4.1 | 4.9 ± 3.7 | 5.8 ± 4.2 | 5.1 ± 3.7 | 5.9 ± 4.3 |
| Median (range) | 4.0 (1–18) | 4.0 (1–15) | 4.0 (1–16) | 4.0 (1–15) | 4.0 (1–16) |
| Duration of treatment (days) | |||||
| Mean ± SD | 152.9 ± 119.2 | 134.9 ± 103.3 | 159.3 ± 121.6 | 138.5 ± 104.2 | 166.0 ± 126.5 |
| Median (range) | 106 (21–385) | 103 (21–384) | 110 (21–385) | 112 (21–384) | 110 (21–385) |
| Cumulative dose (mg/m2) | |||||
| Mean ± SD | 114.4 ± 88.7 | 96.7 ± 71.2 | 134.5 ± 99.2 | 100.6 ± 72.7 | 136.4 ± 101.5 |
| Median (range) | 84.4 (10–445) | 69.2 (20–300) | 100.0 (25–400) | 80 (20–300) | 100 (25–400) |
| ADI (mg/m2/week) | |||||
| Mean ± SD | 5.7 ± 1.4 | 5.4 ± 1.0 | 6.5 ± 1.5 | 5.4 ± 0.9 | 6.4 ± 1.5 |
| Median (range) | 5.6 (1.5–8.4) | 5.4 (2.4–6.9) | 6.6 (2.2–8.4) | 5.5 (2.4–6.7) | 6.4 (2.2–8.4) |
| RDI(%) | |||||
| Mean ± SD | 68.0 ± 16.4 | 64.6 ± 11.6 | 78.3 ± 17.7 | 65.1 ± 11.3 | 76.6 ± 18.4 |
| Median (range) | 67.2 (17.8–101.0) | 64.6 (28.4–82.6) | 79.2 (26.3–101.0) | 65.9 (28.4–80.5) | 77.0 (26.3–101.0) |
C20 20 mg/m2 cabazitaxel, C25 25 mg/m2 cabazitaxel, SD Standard deviation, ADI Actual dose intensity, RDI Relative dose intensity (planned dose intensity = 8.33 mg/m2/week)